Skip to Content
Call Us Today! 855-948-5098
Top
Leading zantac cancer lawyers Over $4 Billion in Verdicts & Settlements
  • PROVEN TRACK RECORD

    Wisner Baum has earned more than $4 billion in verdicts and settlements for clients across all practice areas. We have the resources and experience to take on various opponents and win.

  • History of Success

    Our team has a strong reputation for successfully litigating against Big Pharma.

  • Leaders in the Zantac Litigation

    Wisner Baum’s managing partner R. Brent Wisner serves as co-lead trial counsel for plaintiffs with Zantac lawsuits in California and Delaware state courts.

Zantac Lawsuit

Zantac Lawsuit Update - October 2024

People who developed cancer after taking Zantac (generic: ranitidine) may choose to file a Zantac lawsuit against the drug manufacturers to recover financial compensation for past, present, and future medical bills, lost wages, and other damages.

Zantac lawsuits are ongoing in California and Delaware state courts. In California, attorneys from Wisner Baum and co-counsel have secured several Zantac settlement agreements for clients who allege the heartburn drug caused their cancer. California Zantac attorneys are preparing for trial in 2024. 

In Delaware, over 72,000 lawsuits are moving forward after an order from Judge Vivian Medinilla on May 31, 2024. The order found the opinions of plaintiffs’ experts reliable and admissible, allowing them to testify at trial that Zantac causes cancer. 

Wisner Baum serves on the plaintiffs’ leadership for Zantac cancer cases filed in California State Court and Delaware State Court. 

Information on Zantac Cancer Lawsuits

Check to see if you are eligible to pursue a Zantac lawsuit by filling out this confidential case evaluation form.

Call (855) 948-5098

Contact our experienced attorneys to learn about your legal options. Your consultation is free and confidential.

Zantac Lawsuit FAQS

  • What is Zantac?

    Zantac is the brand name for ranitidine. Chemically known as ranitidine hydrochloride (or ranitidine Hcl), Zantac belongs to a class of drugs called histamine H2-receptor antagonists (or H2 blockers), which decrease the amount of acid produced by the stomach.

    Common uses for Zantac include the treatment of acid reflux, heartburn, and a host of other stomach, throat, and gastrointestinal issues. Others use Zantac for allergies to supplement their treatment regimen.

    Zantac dosage varies between 75 and 150 mg tablets, though some patients take a once daily Zantac 300 mg dosage. Some common Zantac and generic ranitidine products include:

    • Zantac 150 Tablets
    • Zantac 150 Maximum Strength
    • Zantac 150 Maximum Strength Cool Mint
    • Zantac 75 Tablets
    • Wal-Zan 150
    • Wal-Zan 75
    • Heartburn Relief (ranitidine)
    • Acid Reducer (ranitidine)
    • Acid Control (ranitidine)

    Unsure if you took Zantac (ranitidine)? You can use this pill identification app or you can look through this series of Zantac and ranitidine pill images.

  • Why Was Zantac Taken Off the Market?

    Zantac (ranitidine) was taken off the market because the drug contains unacceptable levels of N-Nitrosodimethylamine (NDMA), which is a substance known to cause cancer. Testing of ranitidine drugs showed levels of NDMA above the FDA’s acceptable daily intake limit of 96 nanograms (ng) per day. For example, testing from Connecticut-based online pharmacy Valisure detected NDMA in excess of 3,000,000 ng per tablet when analyzing ranitidine products.

    Valisure tests medications for consistency and quality issues. During testing, the company discovered extremely high levels of NDMA “in every lot tested, across multiple manufacturers and dosage forms of the drug ranitidine.”

    Valisure’s finding was consistent with studies from Stanford University and elsewhere, which found that NDMA in Zantac was likely due to the “inherent instability” of the ranitidine molecule.

    “There’s no acceptable cancer risk for a drug like this,” said David Light, CEO of Valisure.

    Ranitidine is a very unstable molecule. On one side, you have the N (Nitroso). On the other side, you have the DMA (Dimethylamine). When the molecule is exposed to heat, various biological processes in the stomach, and enzymatic reactions throughout the body, it shears apart and reconstitutes as NDMA. But the formation of NDMA is not limited to the reaction in human stomach. Ranitidine can turn into NDMA in the pill bottle itself. In fact, our Zantac lawsuits allege that the drug manufacturers for decades had this problem where ranitidine turned yellow in storage. If it’s yellow, that’s NDMA. They claim they had no idea why this was the case, but our lawsuits say otherwise—they knew.” Ranitidine Cancer Attorney R. Brent Wisner

  • What is a Safe Zantac Replacement?

    Deciding on a safe Zantac replacement is something you should discuss with your doctor. The FDA recommends the following Zantac alternatives:

    • Prilosec (omeprazole) – A proton pump inhibitor (PPI) medication commonly used to treat stomach acid-related conditions, including gastroesophageal reflux disease (GERD).
    • Nexium (esomeprazole) – A proton pump inhibitor (PPI) that reduces stomach acid production and treats GERD, ulcers, and other conditions.
    • Prevacid (lansoprazole) – A proton pump inhibitor (PPI) recommended for short-term ulcer and acid reflux treatment.
    • Pepcid (famotidine) – An H2 blocker that treats ulcers, GERD, and conditions that cause excess stomach acid.
    • Tagamet (cimetidine) – An H2 blocker that reduces acid in the stomach to treat ulcers and acid reflux.
  • Where are Zantac Cases Filed?

    Most Zantac lawsuit cases were initially consolidated in a federal multidistrict litigation (Zantac MDL) before U.S. District Court Judge Robin L. Rosenberg for the Southern District of Florida. However, Judge Rosenberg issued an order granting Zantac defendants’ motion for summary judgment, effectively dismissing all federal cases. Attorneys for the plaintiffs are appealing that decision, and rightfully so, but until those dismissals are resolved, the case is effectively over in the federal system.

    The Zantac lawyers at Wisner Baum didn’t have any cases filed in the MDL. Rather, we filed our cases in California and Delaware state courts—indeed, we formed consolidated proceedings in California and Delaware. Wisner Baum’s managing partner, R. Brent Wisner, serves as co-lead trial counsel in both states.

    The primary state courts with Zantac cases include:

    • California
    • Connecticut
    • Delaware
    • Illinois
    • Pennslyvania
  • Should I Hire a Zantac Lawyer Near Me?

    Many people have the instinct to hire a local attorney to handle their case. In a nationwide mass tort litigation like Zantac, your lawyer’s location is not as important as their experience and track record in successfully resolving cases similar to yours.

    Here’s what you should be looking for in a Zantac lawyer:

    • Proven track record in similar cases
    • Resources needed to take on major corporate defendants
    • Trial-ready litigation team that prepares cases to go before juries to maximize your compensation
    • Compassionate, friendly representation that puts your needs first
    • Availability if and when you have questions about your claim
  • What Will It Cost to Hire a Zantac Attorney?

    We provide free Zantac case reviews to anyone who fills out our contact form or calls our offices. It costs you nothing out of pocket to retain our law firm to represent you and pursue justice and compensation on your behalf. We don’t see a dime until we win your case.
  • How Much Can I Get From Zantac Lawsuit?

    Most of the people who contact our legal team want to know how much their Zantac case is worth. The truth is, we can’t give them a good answer because each case is different. What we can say is that the Zantac litigation will likely end in settlement agreements where cases are ranked using a tier system based on severity of injuries and strength of claim.
  • Has There Been a Zantac Settlement Payout?

    Yes. One of the first Zantac cases scheduled for trial culminated in a settlement worth $500,000. This lawsuit (not our case) alleged generic OTC Zantac caused a man’s esophageal cancer. Additionally, our law firm has helped negotiate several confidential Zantac settlements. While these settlements do not directly affect other cases, they may help set some precedent for the future.

  • Is There a Zantac Class Action?

    The Zantac cancer litigation is a mass tort, which shares similarities with a class action but differs in important ways.

    In a class action, individual plaintiffs are consolidated into a lawsuit seeking economic damages (money paid for a defective or falsely advertised product) rather than personal injury claims.

    A mass tort involves a court (federal or state) grouping similar individual cases and adjudicating them in a single court. Instead of having each lawsuit proceed to trial separately, the cases are transferred to a single court to consolidate pretrial proceedings.

  • My Cancer is Not Listed…Do I Have a Zantac Case?

    At this time, our law firm is unable to pursue cases on behalf of individuals who do not meet the general criteria listed below (How Do You Qualify for a Zantac Lawsuit?). Please understand that this does not mean that you are ineligible to pursue a case or that your injuries are not substantial enough. It simply means that we do not believe that we would be able to successfully pursue a claim on your behalf.
  • How Do You Qualify for a Zantac Lawsuit?

    The general criteria listed below for Zantac lawsuit eligibility is based predominantly on court orders and prevailing scientific research. Please note that Zantac case criteria can change at any time.

    Zantac Use for a Year or More Before Cancer Diagnosis

    Potential Zantac claimants must have taken Zantac or generic ranitidine:

    • With some regularity;
    • Within 10 years of their cancer diagnosis;
    • For a period of at least 12 months.


    Eligible Zantac Cancer Types

    Lawyers are filing heartburn lawsuits for claimants diagnosed with the following types of cancer:

    • Bladder cancer
    • Esophageal cancer
    • Gastric cancer / stomach cancer
    • Liver cancer
    • Pancreatic cancer
    • Prostate cancer
    • Breast cancer
    • Lung cancer
    • Colon cancer

    Those who are eligible and meet certain requirements must submit their claim within a time limit called the statute of limitations. We advise anyone considering a Zantac lawsuit to speak with a ranitidine cancer attorney as soon as possible to ensure they are not time-barred from pursuing a claim.

cONTACT US Today!

We’re Ready to Help
  • Please make a selection.
  • Please enter a response.
  • Please make a selection.
    • Bladder Cancer
    • Esophageal Cancer
    • Liver Cancer
    • Pancreatic Cancer
    • Stomach Cancer
    • Prostate Cancer
    • Colon Cancer
    • Breast Cancer
    • Lung Cancer
  • Please enter a message.
  • Please enter your first name.
  • Please enter your last name.
  • Please enter your email address.
    This isn't a valid email address.
  • Please enter your email address.
    This isn't a valid email address.
  • Please enter your phone number.
    This isn't a valid phone number.
  • Please enter your phone number.
    This isn't a valid phone number.
  • Please enter your City.
  • Please make a selection.
  • Please make a selection.
  • By submitting this form, you expressly consent to receive text, phone call, or email communications from Wisner Baum about your request. Message frequency varies. Message & data rates may apply. Text STOP to opt-out at any time. Acceptable Use Policy

 

Zantac Lawsuit Updates 2024

  • October 28, 2024: Wisner Baum and co-counsel rested our case in Russell v. Boehringer Ingelheim Pharmaceuticals, Inc. We anticipate the trial will continue until mid to late November. 
  • October 9, 2024: GlaxoSmithKline PLC has announced Zantac settlements totaling up to $2.2 billion to resolve over 90% of the pending U.S. state court product liability cases. The lawsuits claim that a discontinued version of the heartburn drug Zantac caused cancer.
  • October 3, 2024: The jury in Russell v. Boehringer Ingelheim Pharmaceuticals, Inc. was finalized yesterday. Opening statements begin today.
  • October 2, 2024: Jury selection is underway in the first Zantac trial in California State Court. Opening statements in Russell v. Boehringer Ingelheim Pharmaceuticals, Inc. to follow.
  • September 27, 2024: The trial of Russell v. Boehringer Ingelheim Pharmaceuticals, Inc., will begin with jury selection on Sept. 30, 2024, in Alameda County Superior Court. This case is the first to go to trial in California to allege ranitidine, the active ingredient in Zantac, causes cancer.  

    Plaintiff John Wayne Russell alleges Zantac caused his bladder cancer after long-term use. Mr. Russell is represented by Wisner Baum’s managing partner R. Brent Wisner and Jennifer Moore of the Moore Law Group.  

    Earlier this week, Judge Noël Wise denied Boehringer Ingelheim’s motion to dismiss Mr. Russell’s claim for punitive damages. This is the first Zantac trial against Boehringer where punitive damages will be at stake.
  • September 19, 2024: Wisner Baum and The Moore Law Group have reached a Zantac settlement agreement in more cases scheduled for trial in California state court. The settlement resolves two lawsuits against GlaxoSmithKline (GSK) filed by plaintiffs John Russell and Annette Hughes. Mr. Russell alleged Zantac caused his bladder cancer and Ms. Hughes alleged Zantac caused her colorectal cancer. Their cases were set for a joint Sept. 30, 2024 trial.     

    Zantac attorneys at Wisner Baum are still proceeding to trial against Boehringer Ingelheim for both Mr. Russell and Ms. Hughes. These will be the first Zantac trials in California. Jury selection begins on Monday, September 30, 2024, before Judge Noël Wise in Alameda County Superior Court. Opening statements are set for Oct. 7, 2024.      
     
  • September 4, 2024: A Connecticut judge refused to dismiss lawsuits filed by Connecticut residents against Zantac makers Boehringer Ingelheim, GlaxoSmithKline (GSK), Pfizer, and Sanofi. The defendants had argued that the court didn’t have jurisdiction over the lawsuits claiming that ranitidine causes cancer because the companies were not based in Connecticut.    

    But the judge ruled that plaintiffs showed “linkage sufficient to support the exercise of specific jurisdiction over the moving defendants.” The ruling also noted that the state “has an interest in adjudicating a claim that its residents suffered injury as a result of a defective or inadequate drug label.”  

    Connecticut may be a viable option for Zantac lawsuits moving forward. 
Continue Reading Read Less
  • August 7, 2024: An Illinois judge declared a mistrial today in a Zantac lawsuit alleging Boehringer Ingelheim’s over-the-counter (OTC) ranitide caused the plaintiff’s prostate cancer. The jury indicated it could not reach a unanimous verdict after deliberating for several days. The parties in the lawsuit are scheduled to return to Cook County's chief judge next week to set a new trial date, and possibly a new trial judge.
  • August 5, 2024: GSK announced in a statement that an Illinois jury concluded the drugmaker was not liable for a plaintiff’s colorectal cancer. 

    Another pending case in Illinois—a prostate cancer case—culminated in a confidential Zantac settlement agreement at the end of July. 

    The Zantac attorneys at Wisner Baum are currently preparing to take a case to trial in California on September 30, 2024. For more information on Zantac trials throughout the country, please visit our Zantac Trial page
  • July 5, 2024: On Monday, Judge Vivian Medinilla of the Delaware Superior Court denied a request from GSK and other pharmaceutical companies to appeal a decision that permits over 70,000 Zantac cancer lawsuits to proceed in state court. Judge Medinilla’s ruling means Zantac manufacturers—including Pfizer, Sanofi, and Boehringer Ingelheim—must seek permission to appeal directly from the Delaware Supreme Court.  

    GSK has already submitted its appeal to the state's highest court. If the Delaware Supreme Court rejects their appeal, the Zantac lawsuits will advance to trial.
  • July 2, 2024: Another Zantac lawsuit has culminated in a settlement. The lawsuit was filed in Illinois state court by a man who developed prostate cancer after taking Zantac. The terms of the Zantac settlement are confidential. 
  • June 1, 2024: Delaware Zantac lawsuits are moving forward. Last Friday, Judge Medinilla issued an orderthat allows plaintiffs’ expert witnesses to testify at trial that Zantac (ranitidine) causes cancer. More than 72,000 claimants in Delaware Superior Court allege exposure to N-Nitrosodimethylamine (NDMA) in Zantac caused their cancer. Zantac lawsuits further allege the drugmaker defendants knew for decades that Zantac could break down into a carcinogen.     

    Wisner Baum’s managing partner, R. Brent Wisner, issued the following statement after Judge Medinilla’s order:  

    “This case has always been about getting the science in front of a jury. Judge Medinilla’s thoughtful order highlights something that often gets lost in the modern world of mass torts—the central role juries must play in holding companies accountable. Now, the writing is on the wall. GSK, Boehringer Ingelheim, and Sanofi will need to answer for their forty years of misconduct, and they will be judged by the very people they lied to.”   

    Read more about the latest news in the Delaware Zantac litigation in our press release
Continue Reading Read Less

Client-Focused Representation

REVIEWS & TESTIMONIALS

We believe our track record speaks for itself. But you don’t have to take our word for it. See what our clients have to say about working with us.

    "I Can’t Imagine a Better Law Firm"

    Multiple lawyers recommended Wisner Baum to me and I have been consistently impressed with the quality of their work.

    - Best Law Firms Survey
    "They Are About Changing the Systems..."

    Wisner Baum are not only amazing attorneys but more importantly, they are activists. They are about changing the systems which got us into trouble in the first place. They understand their role in the process of making change.

    - Kim Witczak
    "Top Legal Minds in the Country"

    The Wisner Baum firm has some of the top legal minds in the country; they are driven, determined, trustworthy, ethical and passionate.

    - From Best Lawyers® Best Law Firms

Wisner Baum Leading Zantac Lawsuits in California and Delaware

Wisner Baum’s managing partner, R. Brent Wisner, serves as  Co-lead Plaintiffs’ Liaison Counsel for the Ranitidine Product Cases, also known as the Ranitidine (Zantac) Judicial Council Coordinated Proceedings (JCCP 5150) in California Superior Court for the County of Alameda. He was also appointed co-lead trial counsel in the Zantac (Ranitidine) Products Liability Litigation (Civil Action No. N22C-09-101 ZAN) in Delaware Superior Court. As of August 2023, there are nearly 85,000 cases filed in California and Delaware. 

Attorneys With Billions in Verdicts and Settlements

Class action lawyers from the national law firm of Wisner Baum represent thousands of people from across the country with personal injury and wrongful death claims against the makers of Zantac:

  • Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of Boehringer Ingelheim Corporation
  • Sanofi US Services Inc., a wholly owned subsidiary of Sanofi S.A.
  • Pfizer, Inc.
  • GlaxoSmithKline, LLC

How We Can Help With Your Zantac Lawsuit

The trial-ready team of attorneys at Wisner Baum intends to hold the makers of Zantac accountable for allegedly concealing the ranitidine cancer link. With more than $4 billion in verdicts and settlements won across all practice areas, we have the experience and track record needed to secure maximum compensation for our clients.

We have filed Zantac lawsuits alleging the drug maker defendants have known for decades that the ranitidine molecule is capable of producing staggering amounts of the carcinogen NDMA when ingested as directed. Rather than warning people about the Zantac cancer risk, the drug makers willingly chose to put profit over people.

Our clients would never have purchased or used this drug had the manufacturers properly disclosed potentially fatal Zantac side effects. Outraged by the recklessness of these companies, we intend to hold them accountable for the damage they have caused.

Wisner Baum Zantac attorneys are in active litigation. If you were diagnosed with cancer after taking Zantac, you maybe eligible to pursue compensation in a Ranitidine lawsuit. Contact us online or call (855) 948-5098 to see if you qualify.

Join the Zantac Cancer Lawsuit

Wisner Baum is one of the leading firms in the Zantac litigation. In practice for nearly 50 years, our firm has earned a reputation for winning big cases against big companies. One of our greatest successes in litigation shares similarities to the Zantac litigation. Our lawsuits against Monsanto (now part of Bayer) involved allegations that a consumer product causes cancer (non-Hodgkin’s lymphoma).

At trial, co-lead counsel R. Brent Wisner delivered the opening and closing statements before the jury. Wisner and his colleagues earned a $2.055 billion jury verdict* for our clients, one of the largest personal injury jury verdicts in U.S. history. A similar case resulted in a $289.2 million jury verdict* on behalf of our client, the second-largest jury verdict in the state of California for 2018.

Put your case in the hands of an experienced legal team that understands what it takes to earn the results clients deserve.

*Jury verdicts later reduced

Continue Reading Read Less